ClickHouse Raises $350 Million Series C to Power Analytics for the AI Era
29.5.2025 16:30:00 CEST | Business Wire | Press Release
ClickHouse, Inc., a leader in real-time analytics, data warehousing, observability, and AI/ML, today announced it has raised $350 million in Series C financing. The round was led by Khosla Ventures, with participation from new investors BOND, IVP, Battery Ventures, and Bessemer Venture Partners, as well as existing investors including Index Ventures, Lightspeed, GIC, Benchmark, Coatue, FirstMark, and Nebius. Today’s round follows earlier investments of over $300 million, bringing total funding to over $650 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529254399/en/
The ClickHouse Founders - Aaron Katz, Yury Izrailevsky, Alexey Milovidov
This combined funding will be used to scale product development, support global expansion, and deepen partnerships with customers and technology providers building the next wave of AI-native applications. In addition to this financing, ClickHouse has secured a $100 million credit facility led by Stifel and Goldman Sachs.
The momentum behind ClickHouse is accelerating: the company grew over 300% during the past year and now serves over 2,000 customers across a range of industries from fintech and transportation to consumer and healthcare. New customers include Anthropic, Tesla, and Argentina’s Mercado Libre, among others. They join companies such as Sony, Meta, Memorial Sloan Kettering, Lyft, and Instacart, as well as AI innovators Sierra, Poolside, Weights & Bases, Langchain, and more.
Today’s announcement was made at ClickHouse’s inaugural user conference, showcasing how enterprises are building data products to meet the demands of the agentic era.
“As AI agents proliferate across data-driven applications, observability, data infrastructure, and beyond, the demand for agent-facing databases like ClickHouse has reached an inflection point. The future of analytics isn’t just dashboards. It’s intelligent agents that interpret data, trigger workflows, and power real-time decisions,” said Aaron Katz, CEO of ClickHouse. “But AI is just one driver. We designed and built ClickHouse from day one to support a broad spectrum of real-time data applications across industries, and our momentum reflects that enterprises are hungry for a platform that can keep up with their scaling ambitions.”
“We invested in ClickHouse because they’re solving one of the most important infrastructure challenges of this era of AI and agents: enabling real-time data platforms that can support both traditional analytics and the growing demands of AI-native workloads,” said Ethan Choi, Partner at Khosla Ventures. “As AI reshapes every industry, the ability to deliver fast, scalable, and cost-efficient analytics is becoming foundational, ClickHouse is poised to become the default engine for next-generation intelligent data products.”
The Next Frontier: Real-Time Analytics for Agentic Workloads
The market traction around ClickHouse is rooted in a fundamental shift: enterprises are no longer just building dashboards or batch reports—they are building real-time, intelligent data platforms that must serve both human and AI agents. Since AI agents can generate queries much faster and at a higher rate than human analysts, agent-facing databases must support low-latency, interactive analytical queries at an increasingly high throughput.
ClickHouse was designed from the ground up to meet this demand. Its high-performance, columnar storage engine enables interactive, analytical queries across massive datasets with minimal latency—perfect for powering AI and ML applications, real-time analytics, cloud data warehousing, and observability workloads.
Built for Speed at Scale: High-Performance Analytics Across Industries
Traditional databases and warehouses are struggling to keep up with this demand. Transactional databases don’t scale for analytical workloads. Meanwhile, traditional data warehouses are optimized for internal, batch-heavy use cases with limited concurrency and slow performance. Finally, search-oriented technologies become prohibitively expensive for structured analytics—using 10x more in storage and compute and limiting the practical range of applications due to cost.
By contrast, ClickHouse offers a purpose-built solution that bridges the gap—combining high-performance analytics with the scalability and concurrency that today’s intelligent, data-driven applications require.
About ClickHouse
ClickHouse is a fast, open-source columnar database management system built for real-time data processing and analytics at scale. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed and concurrency, making it ideal for applications that demand instant insight from massive volumes of data. As AI agents become increasingly embedded in software and are generating far more frequent and complex queries, ClickHouse brings a high-throughput, low-latency engine, purpose-built to meet this challenge. Trusted by leading companies like Sony, Tesla, Anthropic, Memorial Sloan Kettering, Lyft, and Instacart, ClickHouse helps teams unlock insights and drive smarter decisions with a scalable, efficient, and modern data platform. For more information, visit clickhouse.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250529254399/en/
Contacts
Tanya Bragin
VP, Product & Marketing
press@clickhouse.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom